Dianthus Therapeutics (DNTH)

• Market cap: $1.81B
• 1 day: 1.2%
• 5 days: -5.54%
• 1 month: 8.81%
• 3 months: 13.37%
• 6 months: 118.4%
• Year to date: 81.59%
• 1 year: 79.28%
• 5 years: -63.22%
• 10 years: -81.87%
• Sector: Healthcare
• Industry: Biotechnology

About: Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Employees: 78